AAAsrar Alahmadi

Asrar Alahmadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Asrar Alahmadi has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table 1 from Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer

    by Elisa Gobbini, Subhamoy Chakraborty, Ioannis Vathiotis, Roberto Borea, Konstantinos N. Syrigos, Nicolas Girard, Asrar Alahmadi, Christian Rolfo, Triparna Sen

  • Open Access

    Data from Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer

    by Elisa Gobbini, Subhamoy Chakraborty, Ioannis Vathiotis, Roberto Borea, Konstantinos N. Syrigos, Nicolas Girard, Asrar Alahmadi, Christian Rolfo, Triparna Sen

    Immunotherapy has transformed the lung cancer treatment landscape, establishing a role in nearly all histologic subtypes, including non–small cell and small cell lung cancers. However, only a few biomarkers, including PD-L1 tumor proportion score, tumor mutational burden, and microsatellite instability, are currently available, and their predictive value remains inconsistent across different histologies. The biological heterogeneity of lung tumors and the dynamic interplay between systemic therapies and the tumor microenvironment (TME) further complicate biomarker development. At the same time, novel immunotherapeutic strategies, including bispecific antibodies and antibody–drug conjugates, are expanding the spectrum of immune targets beyond conventional checkpoint inhibition, highlighting the need for biomarkers that better reflect the functional state of the TME. In this review, we address the limitations of currently used biomarkers across lung cancer histologies and describe emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling; these have shown promise as histology-independent predictors of response. Robust prospective studies are essential to validate integrated signatures capable of capturing profiles of patients who are most likely to respond to immune checkpoint inhibitors and next-generation treatments.

  • Open Access

    Polygenic Risk Scores for Pancreatic Cancer Risk Prediction and Early Detection: A Systematic Evidence Review of Clinical Utility

    by Mohamed I. Elsaid, Yesung Kweon, Oindrila Bhattacharyya, Yousef Alish, Dongjun Chung, Soledad Fernández, Fode Tounkara, Asrar Alahmadi, Ashish Manne, Electra D. Paskett

    Background/Objectives: Pancreatic cancer carries a five-year relative survival of 13%. Polygenic risk scores (PRS) rank inherited susceptibility across common variants. Prior syntheses pooled PRS association and discrimination, but none asked whether a PRS changes a clinical decision. We synthesized evidence on the clinical utility of PRS for pancreatic cancer risk assessment. Methods: In this PROSPERO-registered review (CRD42024511326), we searched four databases through May 11, 2026, for studies evaluating a PRS for primary pancreatic cancer risk in adults, alone or with clinical predictors. We recorded discrimination as the prerequisite for utility and organized utility across five prespecified domains: threshold-based accuracy, incremental value, calibrated absolute risk, decision-analytic output, and economic impact. We synthesized narratively and appraised risk of bias with PROBAST. Results: Forty-three studies met the inclusion and exclusion criteria, including 25 from the UK Biobank. Ten of 16 standalone discrimination estimates fell between 0.56 and 0.64. Adding PRS to a clinical model increased discrimination by at most 0.05 in general populations. Combined PRS and clinical models exceeded 0.80 only in three diabetes-focused studies. Six studies reported calibration, four reclassification, two decision-curve net benefit, none cost-effectiveness, and 20 had no translational milestone. Thirteen studies were at high risk of bias, with 11 in the analysis domain. Conclusions: Pancreatic cancer PRS discriminates modestly alone and adds most where prior risk is highest. Actionable use awaits an externally validated absolute-risk model with a prespecified threshold and a decision analysis.

  • Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer

    by Elisa Gobbini, Subhamoy Chakraborty, Ioannis Vathiotis, Roberto Borea, Konstantinos N. Syrigos, Nicolas Girard, Asrar Alahmadi, Christian Rolfo, Triparna Sen

    Immunotherapy has transformed the lung cancer treatment landscape, establishing a role in nearly all histologic subtypes, including non–small cell and small cell lung cancers. However, only a few biomarkers, including PD-L1 tumor proportion score, tumor mutational burden, and microsatellite instability, are currently available, and their predictive value remains inconsistent across different histologies. The biological heterogeneity of lung tumors and the dynamic interplay between systemic therapies and the tumor microenvironment (TME) further complicate biomarker development. At the same time, novel immunotherapeutic strategies, including bispecific antibodies and antibody–drug conjugates, are expanding the spectrum of immune targets beyond conventional checkpoint inhibition, highlighting the need for biomarkers that better reflect the functional state of the TME. In this review, we address the limitations of currently used biomarkers across lung cancer histologies and describe emerging immune-related biomarkers encompassing innate immune infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling; these have shown promise as histology-independent predictors of response. Robust prospective studies are essential to validate integrated signatures capable of capturing profiles of patients who are most likely to respond to immune checkpoint inhibitors and next-generation treatments.

  • Open Access

    Data from Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer

    by Triparna Sen, Elisa Gobbini, Khalis Mustafayev, Logan S. Spiegelman, Fatma Nihan Akkoc Mustafayev, Fred R. Hirsch, Asrar A. Alahmadi, Manmeet S. Ahluwalia

    Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.

  • Open Access

    Figure S1 from Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer

    by Triparna Sen, Elisa Gobbini, Khalis Mustafayev, Logan S. Spiegelman, Fatma Nihan Akkoc Mustafayev, Fred R. Hirsch, Asrar A. Alahmadi, Manmeet S. Ahluwalia

    Incidence of brain metastases at diagnosis and prognosis according to lung cancer histology.

  • Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer

    by Triparna Sen, Elisa Gobbini, Khalis Mustafayev, Logan S. Spiegelman, Fatma Nihan Akkoc Mustafayev, Fred R. Hirsch, Asrar A. Alahmadi, Manmeet S. Ahluwalia

    Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.


  • Open Access

    Hepatobiliary Progenitor-like Reprogramming in Liver Metastases

    by Ajit Kumar Sharma, Nobuyuki Takahashi, Yingying Cao, Abhinav Joshi, Sophie Zhuang, Amira Kazi, Michael Nirula, Sarthak Sahoo, Yang Zhang, Rajesh Kumar, et al.

    Metastatic progression requires cancer cells to adapt to the unique constraints of distant organ microenvironments, yet the mechanisms that drive organ-specific adaptations remain poorly understood. Here, we show that the liver actively rewrites metastatic cancer cell identity, driving tumor cells toward a hepatobiliary progenitor-like state. Through integrated transcriptomic, proteomic, metabolomic, and epigenomic analyses of patient-derived rapid-autopsy samples and experimental models, we identify this state as selectively enriched in liver metastases. It is characterized by co-activation of hepatic and biliary/progenitor regulators HNF4A and SOX9 and is observed across multiple epithelial cancers, indicating a conserved response to the hepatic niche. Mechanistically, hepatocyte-derived TGF-β and hypoxia converge to activate a HIF-1α-ACLY axis, increasing nuclear acetyl-coenzyme A availability and histone acetylation at hepatic lineage regulatory elements to drive hepatobiliary reprogramming. This coordinated niche-response program can be captured transcriptionally and is associated with inferior overall survival. Disruption of this pathway suppresses hepatic reprogramming and impairs liver metastatic fitness. These findings identify the liver as an active determinant of metastatic cell fate, linking microenvironmental signaling to metabolic and chromatin remodeling programs that enable lineage plasticity. More broadly, they reveal organ-specific reprogramming as a fundamental principle of metastasis and a therapeutic vulnerability in liver metastases.

  • Open Access

    Supplementary Data from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer

    by Gary Wildey, Ashley M. Shay, Karen S. McColl, Suzy Yoon, Mohammad A. Shatat, Ahmad Perwez, Kyle B. Spainhower, Adam M. Kresak, MaryBeth Lipka, Michael Yang, et al.